Feedback
Settings

Settings

Goto Application

1. WO2007047950 - USE OF SUMOYLATION INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE

PermaLink
Publication Number WO/2007/047950
Publication Date 26.04.2007
International Application No. PCT/US2006/041084
International Filing Date 20.10.2006
IPC
C12N 9/48 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
48acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
C12N 9/50 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
48acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
50Proteinases
C07H 21/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
CPC
G01N 2500/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2500Screening for compounds of potential therapeutic value
G01N 2510/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2510Detection of programmed cell death, i.e. apoptosis
G01N 2800/2835
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
28Neurological disorders
2835Movement disorders, e.g. Parkinson, Huntington, Tourette
G01N 33/5008
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
G01N 33/5014
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
5014for testing toxicity
G01N 33/502
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
5005involving human or animal cells
5008for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
502for testing non-proliferative effects
Applicants
  • CARITAS ST. ELIZABETH MEDICAL CENTER OF BOSTON, INC. [US]/[US] (AllExceptUS)
  • XU, Jin [US]/[US] (UsOnly)
  • ZHONG, Nan (UsOnly)
Inventors
  • XU, Jin
  • ZHONG, Nan
Agents
  • CONLIN, David, G.
Priority Data
60/729,30821.10.2005US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) USE OF SUMOYLATION INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE
(FR) UTILISATION D'INHIBITEURS DE SUMOYLATION DANS LE TRAITEMENT D'UNE MALADIE NEURODEGENERATIVE
Abstract
(EN)
The invention generally provides screening methods for the identification of therapeutic compounds useful for the treatment of a neurodegenerative disease, and related prophylactic and therapeutic compositions and methods.
(FR)
L'invention porte sur des méthodes de criblage utilisées dans l'identification de composés thérapeutiques utiles dans le traitement d'une maladie neurodégénérative, l'invention portant également et sur des compositions et sur des méthodes prophylactiques et thérapeutiques appropriées.
Also published as
EP6826370
US20090023794
Latest bibliographic data on file with the International Bureau
# -